ClinicaliQ Trial Snapshot
- A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Recruiting • Phase III • Gastroenterology • NCT07158242.
- Trial testing a new drug (Afimkibart) for treating moderate-to-severe ulcerative colitis in children, measuring safety and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC). Conditions: Moderately to Severely Active Ulcerative Colitis Interventions: Afimkibart Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 100 participants